Oriola-KD makes changes to management team

Henry Fogels adds acting director general of wholesale business in Russia to his duties

Henry Fogels, general director of Oriola-KD's Pharmaceutical Retail business in Russia (OOO Vitim) has been nominated, in addition to his current duties, to the position of acting general director of Oriola-KD's Pharmaceutical Wholesale business in Russia.

Fogels will continue as a member of Oriola-KD's Group Management Team, being responsible for Oriola-KD's businesses in Russia.

Fogels has replaced Vladimir Knyazev, who left the Espoo, Finland-based company this month.

You may also like

Manufacturing

Oriola-KD to sell healthcare trade business to Mediq

Dutch firm to acquire Oriola-KD businesses across Scandinavia and Europe
Sustainability
Gerresheimer commissions photovoltaic system in Pfreimd

Gerresheimer commissions photovoltaic system in Pfreimd

Approximately 500,000 kWh of solar power annually from own rooftops | Expansion of the share of renewable energy at the site
Analysis
New chemisorption analyser redefines catalyst characterisation

New chemisorption analyser redefines catalyst characterisation

Anton Paar introduces the Autosorb 3300: Advanced flow chemisorption analysis with unprecedented ease of use and automation
Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Pharma 5.0
FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

The new AI-powered platform combines autonomous digital workers, interoperable healthcare data and compliance tools to help pharmaceutical manufacturers, medical device companies and healthcare providers scale AI adoption
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Manufacturing
Vacuubrand Vario® chemistry diaphragm pumps

Vacuubrand Vario® chemistry diaphragm pumps

The ideal solution for your laboratory
Subscribe now